KR20250067190A - 키메라 폭스바이러스 조성물 및 이의 용도 - Google Patents

키메라 폭스바이러스 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20250067190A
KR20250067190A KR1020257014373A KR20257014373A KR20250067190A KR 20250067190 A KR20250067190 A KR 20250067190A KR 1020257014373 A KR1020257014373 A KR 1020257014373A KR 20257014373 A KR20257014373 A KR 20257014373A KR 20250067190 A KR20250067190 A KR 20250067190A
Authority
KR
South Korea
Prior art keywords
virus strain
nucleic acid
vaccinia virus
acid sequence
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014373A
Other languages
English (en)
Korean (ko)
Inventor
유만 퐁
난하이 첸
Original Assignee
시티 오브 호프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시티 오브 호프 filed Critical 시티 오브 호프
Publication of KR20250067190A publication Critical patent/KR20250067190A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020257014373A 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도 Pending KR20250067190A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof
KR1020237024342A KR20230113832A (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024342A Division KR20230113832A (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20250067190A true KR20250067190A (ko) 2025-05-14

Family

ID=61163330

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257014373A Pending KR20250067190A (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도
KR1020237024342A Ceased KR20230113832A (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도
KR1020197006987A Active KR102557818B1 (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237024342A Ceased KR20230113832A (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도
KR1020197006987A Active KR102557818B1 (ko) 2016-08-09 2017-08-09 키메라 폭스바이러스 조성물 및 이의 용도

Country Status (11)

Country Link
US (2) US12084687B2 (enExample)
EP (1) EP3497209A4 (enExample)
JP (4) JP7023929B2 (enExample)
KR (3) KR20250067190A (enExample)
CN (3) CN118853594A (enExample)
AU (2) AU2017311380A1 (enExample)
BR (1) BR112019002646A2 (enExample)
CA (1) CA3033512A1 (enExample)
MX (1) MX2019001672A (enExample)
RU (2) RU2757002C2 (enExample)
WO (1) WO2018031694A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP2018510143A (ja) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
EP3419648A4 (en) 2016-02-25 2019-09-11 Memorial Sloan-Kettering Cancer Center REPLICATING COMPETENTES WEAKENED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CA3033512A1 (en) * 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
JP2021516957A (ja) * 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
US12252702B2 (en) 2018-09-15 2025-03-18 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
JP2025528219A (ja) 2022-08-18 2025-08-26 トランジェーヌ キメラポックスウイルス
AU2024280931A1 (en) * 2023-05-26 2025-11-27 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) * 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
EA012723B1 (ru) * 2002-11-25 2009-12-30 Бавариан Нордик А/С Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение
AU2004289953B2 (en) * 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
DK2212423T3 (en) * 2007-11-19 2015-03-16 Transgene Sa oncolytic poxvirus vectors
CA2795695A1 (en) * 2010-04-09 2011-10-13 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
CN104768567B (zh) 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CA3033512A1 (en) * 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof

Also Published As

Publication number Publication date
JP2019524131A (ja) 2019-09-05
KR102557818B1 (ko) 2023-07-20
KR20190038626A (ko) 2019-04-08
CN118853594A (zh) 2024-10-29
KR20230113832A (ko) 2023-08-01
EP3497209A4 (en) 2020-07-29
AU2017311380A1 (en) 2019-03-28
RU2019106319A3 (enExample) 2021-03-17
RU2019106319A (ru) 2020-09-17
BR112019002646A2 (pt) 2019-10-08
WO2018031694A1 (en) 2018-02-15
RU2021128158A (ru) 2022-04-07
JP2025072482A (ja) 2025-05-09
MX2019001672A (es) 2019-06-06
JP7631485B2 (ja) 2025-02-18
JP2024026191A (ja) 2024-02-28
AU2023270200A1 (en) 2024-01-25
RU2757002C2 (ru) 2021-10-08
CN110199018A (zh) 2019-09-03
JP7395628B2 (ja) 2023-12-11
JP2022065034A (ja) 2022-04-26
US20190218522A1 (en) 2019-07-18
US12084687B2 (en) 2024-09-10
US20250084384A1 (en) 2025-03-13
EP3497209A1 (en) 2019-06-19
CN118834840A (zh) 2024-10-25
CA3033512A1 (en) 2018-02-15
CN110199018B (zh) 2024-06-07
JP7023929B2 (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
KR102557818B1 (ko) 키메라 폭스바이러스 조성물 및 이의 용도
CN111163803B (zh) 表达car t细胞靶物的溶瘤病毒及其用途
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
AU2013312198B2 (en) Fluorescence activated cell sorting (FACS) enrichment to generate plants
RU2757933C2 (ru) Новые генно-инженерные вирусы осповакцины
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
AU2017353868B2 (en) Synthetic chimeric poxviruses
AU2018203259A1 (en) Recombinant HCMV and RhCMV vectors and uses thereof
KR102205348B1 (ko) 외인성 항원을 포함하는 인간 시토메갈로바이러스
KR20150043540A (ko) Fad3 성능 유전자좌 및 표적화 파단을 유도할 수 있는 상응하는 표적 부위 특이적 결합 단백질
CN116348135A (zh) 基于重组痘病毒的抗SARS-CoV-2病毒疫苗
RU2673715C2 (ru) Вакцина против haemophilus parasuis серологического типа 4
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
CN115397998A (zh) 由天然或合成dna产生的基于痘病毒的载体及其用途
KR20230136600A (ko) 안정적인 세포주에서 효율적인 성장을 가능하게 하는아프리카 돼지 열병 백신의 게놈 결실
CN117222418A (zh) 增强肿瘤中的hla单倍型表达多样性以扩大肿瘤细胞对tcr-t疗法的敏感性的方法
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers
HK40000936B (zh) 新型基因重组牛痘病毒

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250429

Application number text: 1020237024342

Filing date: 20230717

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250526

Comment text: Request for Examination of Application